Nuveen’s Aligos Therapeutics ALGS Stock Holding History

Nuveen’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,410	Closed	-$172K	–	3236
2022 Q1	$172K	Sell	2,410 -961	-29%	-$77K	﹤0.01%	3212
2021 Q4	$1M	Sell	3,371 -158	-4%	-$57.6K	﹤0.01%	2862
2021 Q3	$1.37M	Buy	3,529 +960	+37%	+$380K	﹤0.01%	2848
2021 Q2	$1.31M	Buy	2,569 +1,595	+164%	+$1.02M	﹤0.01%	2900
2021 Q1	$553K	Buy	974 +312	+47%	+$208K	﹤0.01%	3076
2020 Q4	$458K	Buy	+662	New	+$322K	﹤0.01%	3057

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nuveen's ALGS Position: Q2 2022 in Review

Nuveen sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 2,410 shares — an estimated $172K sold.

Nuveen first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $1.37M in Q3 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

Nuveen reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
Nuveen sold 2,410 Aligos Therapeutics shares in Q2 2022, an estimated $172K.
Nuveen first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
Nuveen's Aligos Therapeutics position peaked at $1.37M in Q3 2021.
59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.